Methods for the identification of agents the bind to exo-sites of proteins are provided. Agents identified by the methods described herein and pharmaceutical compositions comprising the identified agents are also provided. Methods of using an identified agent for the treatment or prevention of a disease, disorder, or condition are also provided, including methods of treating or preventing a disease associated with reduced, elevated, or ectopic expression or aberrant activity of a protein comprising an exo-site.

Methods for the identification of agents the bind to exo-sites of proteins are provided. Agents identified by the methods described herein and pharmaceutical compositions comprising the identified agents are also provided. Methods of using an identified agent for the treatment or prevention of a disease, disorder, or condition are also provided, including methods of treating or preventing a disease associated with reduced, elevated, or ectopic expression or aberrant activity of a protein comprising an exo-site.

Disclosed are methods for preparing a medicament for treating a malignant tumor, along with cell membranes prepared by such methods and the use thereof, in which the individual communication structure between the malignant tumor and the immune system is ascertained based upon a tissue sample containing cells of the malignant tumor by determining a malignant tumor-specific expression pattern of histocompatibility antigens (Human Leucocyte Antigen, HLA) on said tissue sample, masking or removing at least a part of the expression pattern present on the cells of the tissue sample that is capable of exerting an inhibitory effect on immunocompetent cells, and preparing an individual vaccine for eliciting a specific immunological response by lysing those cells on which a part of the expression pattern has been masked or removed.

Disclosed are methods for preparing a medicament for treating a malignant tumor, along with cell membranes prepared by such methods and the use thereof, in which the individual communication structure between the malignant tumor and the immune system is ascertained based upon a tissue sample containing cells of the malignant tumor by determining a malignant tumor-specific expression pattern of histocompatibility antigens (Human Leucocyte Antigen, HLA) on said tissue sample, masking or removing at least a part of the expression pattern present on the cells of the tissue sample that is capable of exerting an inhibitory effect on immunocompetent cells, and preparing an individual vaccine for eliciting a specific immunological response by lysing those cells on which a part of the expression pattern has been masked or removed.

Disclosed are methods and systems for screening covalent ligand libraries to identify potential covalent inhibitors. The methods and systems may also be used to generate a covalent inhibitor library from natural ligands. These covalent inhibitors bind to the receptor irreversibly after initial reversible binding. The covalent inhibitor identified or designed using the present methods may specifically bind to and covalently modify a receptor.

Methods for the identification of agents the bind to exo-sites of proteins are provided. Agents identified by the methods described herein and pharmaceutical compositions comprising the identified agents are also provided. Methods of using an identified agent for the treatment or prevention of a disease, disorder, or condition are also provided, including methods of treating or preventing a disease associated with reduced, elevated, or ectopic expression or aberrant activity of a protein comprising an exo-site.

The present invention includes a multivalent glycan microarray for detection of glycan-binding proteins. The multivalent glycan microarray allows a multivalent presentation of glycan on a microarray substrate, which can enhance binding of the glycan binding protein to the glycan microarray. The multivalent microarray includes a solid substrate having one or more branched polymers bonded to it via one or more silane-based linker reagents. The branched polymer in turn is bonded to a glycan, via one or more bifunctional linkers to form the multivalent glycan microarray. Nonspecific binding of glycan binding proteins to the multivalent glycan microarray can be reduced by using a blocking reagent coated on to the microarray substrate, which includes a polyethylene glycol surfactant attached to the solid substrate via a self-crosslinking azido-functionalized silane. Methods for making multivalent glycan microarrays and methods for using same to detect glycan-binding proteins are also disclosed.

Devices, systems and methods for affinity reagent and catalyst discovery employing a library on a bead HTS platform, each bead comprising affixed non-natural polymers of a distinct bioactive monomer with sequence pre-defined branching and folding in tertiary structures, and fiber-optic array scanning technology.

The present invention provides a library comprising 110.sup.2 to 110.sup.8 compounds, wherein the compounds have the following structure where a first core block (first CB), a first linker (first L), and a second core block (second CB) are covalently linked: (first CB)-(first L)-(second CB), wherein the library comprises two or more types of first CB, two or more types of first L, and two or more types of second CB, and the library is constituted by one or two or more mixtures comprising 110.sup.2 to 110.sup.5 of the compounds.

The present invention provides a library comprising 110.sup.2 to 110.sup.8 compounds, wherein the compounds have the following structure where a first core block (first CB), a first linker (first L), and a second core block (second CB) are covalently linked: (first CB)-(first L)-(second CB), wherein the library comprises two or more types of first CB, two or more types of first L, and two or more types of second CB, and the library is constituted by one or two or more mixtures comprising 110.sup.2 to 110.sup.5 of the compounds.